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ABSTRACT 
Interaction thermodynamics between warfarin, a very popular anticoagulant, and Sudlow I binding site of 
human (HSA) or bovine (BSA) serum albumin have been examined in strictly controlled experimental 
conditions (HEPES buffer 50 mM, pH 7.4 and 25 ºC) by means of isothermal titration calorimetry (ITC), 
fluorescence spectrometry (FS) and frontal analysis capillary electrophoresis (FA/CE). Each technique is based 
on measurements of a different property of the biochemical system, and then the results allow a critical 
discussion about the suitability of each approach to estimate the drug-protein binding parameters. The 
strongest interaction step is properly evaluated by the three assayed approaches being the derived binding 
constants strongly consistent: from 4x104 to 7x104 for HSA and from 0.8x105 to 1.2x105 for BSA. Binding 
enthalpy variations also show consistent results: -5.4 and -5.6 Kcal mol-1 for HSA and -4.3 and -3.7 Kcal mol-1 
for BSA, as measured by ITC and FS, respectively. Further high order interaction events for both albumins are 
detected only by FA/CE.  
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1. Introduction 1 
Albumin, the most abundant protein in plasma and serum, is a water-soluble macromolecule, which permits 2 
to maintain the plasma oncotic pressure and modulate the fluid distribution among body compartments. It 3 
shows also considerable buffering, antioxidant and pseudo-enzymatic abilities. Native albumin is built up 4 
from three homologous domains (I, II and III), each one with two distinct subdomains, named A and B. Drugs 5 
and other compounds bind mainly to two of them: Sudlow I or acidic drug binding site, placed on subdomain 6 
IIA, and Sudlow II or benzodiazepine binding site, located on subdomain IIIA [1,2]. Thus, albumin plays a 7 
relevant role on the pharmacokinetics of drugs. Albumin molecular structure strongly depends on its origin 8 
and only about 70% of the macromolecule is a common moiety for any kind of albumin. Thus, it has been 9 
noticed about 25-30% of variability in amino acid sequences according to the albumin origin, human (HSA), 10 
bovine (BSA) or others [2,3]. For example, HSA has only one tryptophan residue (Trp-214) while BSA contains 11 
two of them (Trp-134 and Trp-213), being the single Trp-214 of HSA located in a similar microenvironment 12 
as the Trp-213 of BSA. BSA Trp-134 is in a rather superficial site and shows a lesser hydrophobic character. 13 
Consequently, rather different binding activities of both albumins can be expected. Although HSA is usually 14 
preferred in pharmacological studies, BSA is often selected because of veterinary conveniences and easier 15 
availability. In recent and comprehensive reviews on the nature of HSA Sudlow I [4], Abou-Zied states that it 16 
is able to bind a variety of ligands by adapting its binding pockets. Moreover, the site binding ability strongly 17 
depends on the number of trapped water molecules, which increases with the unfolding and refolding HSA 18 
sample past. Then, binding values between a particular drug and HSA Sudlow I site significantly depend on 19 
the quality of the protein sample. Literature do not show details about the BSA Sudlow I behavior, but it 20 
seems plausible to expect similar binding ability constrictions. 21 
Warfarin is a well-known anticoagulant drug commonly used in the prevention of thrombosis and 22 
thromboembolism. It helps the blood to flow freely around the body stopping the clots formation and playing 23 
an essential role on the drug pharmacokinetics [4]. From a physicochemical point of view, warfarin shows 24 
moderate acidity (pKa = 5.0) [5], significant lipophilicity (log Po/w= 3.2, log DpH=7.4 = 0.9) [6,7] and low aqueous 25 
intrinsic solubility (S0 = 5.3 mg L-1) [8]. Many studies point out warfarin as an albumin Sudlow I site marker 26 
[4,9], despite Dockal et al. [10] indicate the indispensable structural contributions of subdomain IIB and 27 
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domain I. Warfarin has been used in studies about displacement reactions for a variety of albumin-friendly 28 
drugs. Nevertheless, to interpret rightly the results, it is convenient to know precisely the binding parameters 29 
of warfarin itself with albumin. Literature values about stoichiometry and energetics of warfarin interactions 30 
with HSA or BSA at physiological pH are summarized in Table 1.  31 
The aim of this work is to establish reliable binding profiles of warfarin with HSA and BSA, in environments 32 
close to the physiological ones. Several common techniques and strictly controlled experimental conditions 33 
have been chosen to contrast efficiently the binding values derived from each approach. Thus, isothermal 34 
titration calorimetry (ITC), fluorescence spectrometry (FS), and frontal analysis capillary electrophoresis 35 
(FA/CE) have been selected. As well known, ITC is able to measure directly the energy and it is, in some sense, 36 
the reference approach. By contrast, FS is focused on the quenching effect of drug on the protein intrinsic 37 
fluorescence whereas FA/CE is based in the estimation of the bonded drug and total protein concentrations 38 
ratio when electrophoretic mobility of the protein equals that of the drug-protein complex. Thus, the two 39 
last approaches allow the determination of stoichiometry and binding constant as significant interaction 40 
parameters. Selected techniques show different sensitivity limits and, then, not all of them are able to 41 
measure properly hypothetical successive binding steps [11,12]. Consequently, a critical comparison about 42 
the binding parameters achieved by the tested techniques on a relatively simple biological interaction (just a 43 
well-known acidic drug binding, mainly, the Sudlow I site of native albumin), using albumin of two biological 44 
origins (HSA and BSA), in strictly controlled conditions (HEPES buffer, pH=7.4, I=50 mM, T=25 ºC) is 45 
performed. Results and conclusions of this work should facilitate further studies in which warfarin is involved, 46 
such as its displacement by other drugs with higher affinity with the albumin. 47 
 48 
2. Experimental 49 
 50 
2.1 Chemicals  51 
Sigma-Aldrich (St Louis, MO, USA) human serum albumin (HSA) (99%) and bovine serum albumin (BSA) 52 
(>99%) were used after spectrophotometric verification of purity. Sigma-Aldrich warfarin (>98%) and (N-2-53 
hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES) (>99.5%) were used as received. To adjust the 54 
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working pH, 0.5 M NaOH (Titrisol, Merck, Darmstadt, Germany) or 0.5 M HCl (Titrisol, Merck) were employed. 55 
Na2HPO4 (>99%) and KH2PO4, KCl, NaCl (>99.5%) from Merck are used too. To prepare the buffer and the 56 
sample solutions, and to standardize and clean the microcalorimeter, water purified by a Milli-Q-plus system 57 
with a resistance higher than 18 MΩ·cm was used. 58 
A 0.2 M HEPES buffer solution (pH 7.4 and ionic strength 50 mM) previously neutralized with NaOH was 59 
prepared. An adequate amount of HCl was added to an aliquot of the previous solution to get the chosen pH 60 
value and lastly diluted to a final concentration of 50 mM. Working in this way the buffer concentration 61 
equals its ionic strength, which is calculated assuming that zwitterions do not contribute to the ionic strength 62 
of the solution [12]. PBS buffer solution (pH 7.4, 140 mM of chloride and 150 mM ionic strength) was 63 
prepared by mixing 1.5 mM KH2PO4, 8.1 mM Na2HPO4, 137 mM NaCl and 2.7 mM KCl, and final correction to 64 
get the selected pH. The ionic strength of the HEPES buffer was set at 50 mM to avoid the Joule effect in the 65 
EC measurements, that occurred over 100 mM. This condition was kept constant when using the other two 66 
analytical techniques to better compare the results. In the case of the measurements in PBS solutions by FS, 67 
it was used a concentration of phosphates of 10 mM (150 mM ionic strength) because under these conditions 68 
the FS measurements are performed closer to the in vivo medium.  69 
 70 
 71 
2.2   ITC titrations 72 
 73 
2.2.1 Instruments 74 
A Microcal VP-ITC (MicroCal, LLC, Northampton, MA, USA) titrator was used. Working solutions were 75 
degassed by means of a Thermovac (MicroCal, LLC) vacuum degasser. The instrumental response was 76 
checked by means of the chelation reaction of Ca2+ with EDTA [13]. A Crison micro-pH 2002 potentiometer 77 
(Crison Instruments, Alella, Spain) equipped by a Crison 5014 combination electrode with a precision of ±0.1 78 
mV (±0.002 pH units) was used for pH measurements. The electrode system was calibrated with ordinary 79 
aqueous buffers of pH 4.01 and 7.00. 80 
 81 
5 
 
2.2.2 Procedure 82 
Albumin and warfarin were solved with HEPES buffer solution. Both HSA and BSA solutions were in the 0.01 83 
to 0.02 mM range, and the concentration of drug solutions varied from 0.2 to 0.5 mM. Prior to their use, all 84 
solutions were degassed for a period of 5 min at 24 ºC. Titrations were performed at 25.0±0.2 ˚C. The power 85 
reference was 10 µcal s-1 and the stirring rate was 290 rpm to ensure rapid mixing. The injection volume was 86 
8 µL and the interval between injections was 240 s to warrant the equilibrium in each titration point. Each 87 
titration involved 29 independent titrant additions. The syringe was filled with the warfarin solution whereas 88 
the albumin was in the cell. Background titrations were performed according to: a) identical titrant solution 89 
with the cell filled just with the buffer and b) successive buffer additions to the albumin solutions. These 90 
measurements allow the determination of the background heat to be subtracted to the main titrations. 91 
Moreover, the dilution heat of the drug-protein complex was evaluated by successive buffer additions to the 92 
complex solutions. Each assay was repeated several times. 93 
 94 
2.2.3 Calculations 95 
Origin 7.0 software supplied by Microcal was used for data treatment. Experimental data were collected 96 
automatically and analyzed to get the interaction stoichiometry, n, and the binding quantities associated to 97 
the interaction event, ΔH and Kb. The suitable adjusting model (one, two or sequential binding sites) should 98 
be introduced into the software. 99 
 100 
2.3 Fluorimetric measurements 101 
 102 
2.3.1 Instruments 103 
Fluorescence measurements were performed on a Cary Eclipse Fluorescence Spectrophotometer from 104 
Agilent Technologies (Sta Clara, CA, USA) using a 1 cm path length quartz cuvette, a medium scan speed, slit 105 
widths with a nominal band-pass of 5 nm for both excitation and emission, and a Savitzky-Golay smooth of 106 
19. The mentioned Crison micro-pH 2002 pH meter was used for pH measurements. A magnetic heater stirrer 107 
(Agimatic-N, JP Selecta, Abrera, Spain) was used too. 108 
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 109 
2.3.2 Procedure 110 
First, the emission spectra of warfarin (30 M in HEPES or PBS buffer, excitation wavelength: 315 nm), HSA 111 
(5 M in HEPES or PBS buffer, excitation wavelength: 284 nm) and BSA (5 M in HEPES or PBS buffer, 112 
excitation wavelength: 287 nm) were recorded. Warfarin, HSA and BSA showed maximum emission signals 113 
at 392 nm, 344 nm, and 346, respectively. To avoid warfarin interference in HSA and BSA fluorescence 114 
quenching evaluation, measurements were done using the Synchronous mode at =20 nm (em=284 nm for 115 
HSA and 287 nm for BSA). Then, the linear range of HSA and BSA fluorescence was evaluated. In working 116 
conditions, the linear range for both albumins was between 0.5 and 8 µM. Therefore, 5 µM HSA or BSA was 117 
the chosen concentration.  118 
Quenching studies were carried out by titration. The albumin (5 M, 3 mL) was placed in the cuvette and the 119 
solution was taken up to the temperature under study (18, 25, 30 or 37 ± 1 ºC) using a water bath and a 120 
magnetic stirrer. The initial fluorescence synchronous spectrum was recorded. Nine successive additions of 121 
warfarin (312.5 M in HEPES or PBS buffer, 7 L) and five new additions of warfarin (625 M in HEPES or PBS 122 
buffer; 5, 8, 11, 14 and 17 L) were done. After each addition, the solution in the cuvette was stirred (3 min, 123 
900 rpm) to allow the temperature equilibration and the reaction happening. Finally, the fluorescence was 124 
measured in the synchronous mode.  125 
 126 
2.3.3 Calculations 127 
The experimental data were exported from the Cary Eclipse Scan Application software to an Excel sheet 128 
(Microsoft, Redmond, WA, USA), and the fluorescence data were corrected for the dilutions carried out along 129 
the titration. 130 
Fluorescence measurements at various temperatures (from 18 to 37 ºC) were performed and the derived 131 
Stern-Volmer constant values (KSV) were calculated by means of Eq. 1  132 
    
ிబ
ி
= 1 + 𝐾ୗ୚[𝐷௧௢௧௔ ]  [Eq. 1] 133 
where F0 is the initial albumin fluorescence, F is the albumin fluorescence after the quencher addition, and 134 
[Dtotal] is the total drug concentration. 135 
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The interaction stoichiometry, n, and the binding constant, Kb, were calculated using two different 136 
approaches. The first one uses a linear equation fitting, Eq. 2. 137 
          138 
[Eq. 2] 139 
        140 
The second approach involves a non-linear equation (Eq. 3) which includes the free drug concentration (in 141 
the second term of the right side) and the total protein, Ptotal , concentration 142 
                                               143 
 [Eq. 3] 144 
 145 
The Excel solver tool allows an easy estimation of n and Kb quantities. The enthalpy variation, ΔH0, was 146 
calculated using the van't Hoff equation, Eq. 4, where ΔS0 stand for the entropy variation involved in the 147 
binding event 148 
[Eq. 4]             149 
         150 
2.4 FA/CE measurements 151 
 152 
2.4.1 Instruments 153 
An Agilent capillary electrophoresis equipped with a diode array detector operating at 214 nm was used. The 154 
measurements were performed at 25.0±0.1˚C on an uncoated fused-silica capillary (50 cm effective length x 155 
50 µm internal diameter) from Polymicro Technologies (Phoenix, AZ, USA). The working conditions included 156 
the application of a 15 kV voltage and positive polarity. For pH measurements, the Crison micro-pH 2002 pH 157 
meter described in Section 2.2.1 was used. 158 
 159 
2.4.2. Procedure 160 
Before first use, any new capillary was conditioned as follows: 10 min with water, 20 min with 1.0 M NaOH, 161 
5 min with water, 10 min with 0.1 M NaOH, 5 min with water and, finally, 20 min with the running buffer. 162 
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Before each working session, the capillary was rinsed 5 min with water, 10 min with 0.1 M NaOH, 5 min with 163 
water and 20 min with the running buffer. Finally, between runs the rinsing sequence was 1 min of water, 2 164 
min of 0.1 M NaOH, and 3 min with the running buffer. At the end of the working session, the capillary was 165 
rinsed again with water for 10 min. 166 
HEPES buffer was used as the separation solution. Calibration curve was built from free warfarin solutions 167 
(2-250 µM for HSA and 8-530 µM for BSA). Constant albumin concentration (12 µM for HSA and 57 µM for 168 
BSA) and variable warfarin concentration (6-240 µM for HSA and 21-460 µM for BSA) solutions, all of them 169 
in HEPES buffer, were also prepared. To obtain the "plateau" signal the sample was injected 170 
hydrodynamically at 0.5 psi for 80 s.  171 
 172 
2.4.3 Calculations 173 
Experimental data were exported from the Agilent CE Chem Station software to an Excel sheet to record the 174 
“plateau” height and were treated according to Eq. 5 175 
                                           𝑟 = [஽್೚ೠ೙೏]
[௉೟೚೟ೌ೗]
= ∑ 𝑛௜
௄್೔[஽೑ೝ೐೐]
ଵା௄್೔[஽೑ೝ೐೐]
௠
௜ୀଵ [Eq. 5] 176 
where [Dbound] and [Dfree] stand for the concentration of the bound and free drug, respectively, and [Ptotal] for 177 
the total concentration of protein. ni is the maximum number of the equivalent binding sites on the protein 178 
and Kbi the associated binding constant. The symbol m denotes the total number of different binding sites by 179 
a particular drug-protein system and r stands for the ratio between the concentrations of bound drug and 180 
total protein [11]. Interaction parameters have been calculated by direct adjust of experimental points to Eq. 181 
5 through Excel software using a supplementary optimization Excel Macro [14]. Nevertheless, the Scatchard 182 
and Klotz approaches have been also considered because their linearized models facilitate an easy view of 183 
the successive interactions and also the dispersion of the experimental data irrespective to the considered 184 
model [11]. 185 
 186 
3. Results and discussion  187 
Table 1 compiles literature values for warfarin interactions with both albumins, HSA and BSA, derived from a 188 
variety of approaches performed in similar experimental conditions. The whole pool of values shows that 189 
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some works report just one drug-protein binding event but some others split the global interaction into two 190 
consecutive steps. The first group involves the measurements made by ITC or FS, that is, by analytical tools 191 
able to measure efficiently from moderate to high affinity events. By contrast, the works included in the 192 
second group were performed by any of two separation techniques, CE/FA or equilibrium dialysis (ED), which 193 
are able to evaluate properly weak and moderate binding interactions [11]. The only exception is reported 194 
by Dockal et al. [10] in a FS study made with HSA and several of its recombinant fragments, which leads to a 195 
two-steps interaction without any indication about the irrespective binding stoichiometries. The mentioned 196 
technique-dependent sensitivity ranges were experimentally verified for ITC and FA/CE in a previous study 197 
about the interactions of some anti-inflammatory drugs with albumin, in which Sudlow II site is directly 198 
involved. It was concluded that a suitable combination of these complementary techniques could lead to 199 
reliable binding profiles [12]. Table 1 shows also that the stronger binding event (or the unique one) implies, 200 
in many instances, a binding constant value around 105 for both albumins. Reported stoichiometry is close 201 
to the unity with the exception of the ITC results for warfarin-BSA interaction, which is much higher [9]. In all 202 
two-step binding reports, the differences between the consecutive binding constant values are between one 203 
and two orders of magnitude and the calculated stoichiometry for the second event ranges between 2 and 204 
3. These data point out a relatively strong specific interaction of warfarin with both albumins and additional 205 
interactions associated to weaker binding episodes.  206 
Table 1 shows also that almost all literature studies were done in phosphate buffer (PBS). However, 207 
phosphate, as well as citrate, borate and succinate, have some disadvantages for studies of biological or 208 
complex systems. Thus, PBS has a poor buffering capacity above pH 7.5 since its dissociation constant is about 209 
6.8 at plasmatic ionic strength and, in addition, it is an active participant in many biochemical processes, 210 
inhibiting the enzymes catalytic role for instance. PBS also demonstrate complexing capabilities with 211 
polyvalent cations and can inhibit several metal ion-dependent biochemical reactions. On the contrary, PIPES, 212 
HEPES, MES and MOPSO, are adequate substitutes of Tris or PBS showing better chemical behavior than 213 
other zwitterionic buffers and they have been, recently,  strongly recommended [15]. Thus, despite some 214 
warnings about possible interferences of HEPES with ligands binding HSA (Biacore Symposium 2002, Chicago, 215 
Illinois, 1-17), it has been selected in present work as a suitable option. 216 
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 217 
3.1 In-house experimental results vs. literature data 218 
 219 
3.1.1 ITC measurements 220 
To get the best working conditions, several titrations with different concentration ratios between warfarin 221 
and HSA or BSA have been tested. The poor aqueous solubility of warfarin has compelled to select much 222 
diluted solutions being the best titration curves those with an initial drug-albumin ratio about 17 for HSA 223 
titrations and 20 for BSA titrations, shown in Figure 1. In both instances, calorimetric curves show an enthalpy 224 
gap between the end of the jump and the blank signal, which suggests additional warfarin-albumin 225 
interactions. Derived binding parameters are gathered in Table 2. 226 
Regarding ITC literature data for warfarin-HSA interaction, it should be pointed out the strong agreement 227 
between values obtained in phosphate and MOPS buffers both at the same ionic strength (100 mM) [16],and 228 
that derived in this work from HEPES buffer (50 mM), see Tables 1 and 2. They show that ionic strength and 229 
buffer agents are irrelevant irrespective the involved thermodynamic binding quantities (notice the buffer 230 
deprotonation molar enthalpy values: ΔHdiss(H2PO4-)= 3.6 kJ mol-1, ΔHdiss(MOPS)= 21.1 kJ mol-1and ΔHdiss(HEPES)= 20.4 231 
kJ mol-1 [17]). Thus, it is concluded that the binding reaction is not coupled with gain or release of protons by 232 
HSA or warfarin [18]. Therefore, the measured enthalpy variation should be very close to the true drug-233 
albumin binding enthalpy since no additional side reactions in the working cell are foreseeable. However, 234 
data derived from Tris (100 mM) solutions show a higher binding constant, which could be attributed to the 235 
very low buffer capacity of Tris at pH 7.13 and, then, to some heat contribution of buffer itself (pKa(TrisH+)= 236 
8.07; ΔHdiss(TrisH+)= 47.45 kJ mol-1 [17]). In any case, reported binding constant [16] is consistent with most 237 
values compiled in Table 1. 238 
Only one literature reference is devoted to ITC determination of warfarin-BSA interaction but no associated 239 
enthalpy datum is stated. Surprisingly, it reports a very high stoichiometry value. The authors claim that the 240 
raw data seem to point out that the drug binds to albumin at more than one binding site and conclude that 241 
warfarin-BSA is not a good model system for protein-ligand interactions [9]. Titrations made in this work also 242 
point out high stoichiometry and a binding constant somewhat higher than the reported value. 243 
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 244 
3.1.2 FS measurements 245 
The in-house fluorescence measurements were performed at various temperatures and fitted to Stern-246 
Volmer relationships in order to estimate the KSV values (Eq. 1). The results, gathered in Table 3, allow the 247 
verification of the static character of the warfarin quenching effect on albumin fluorescence [19]. Therefore, 248 
interaction parameters can be calculated by means of the most common approach, Eq. 2, despite it involves 249 
the statement that free and total drug concentrations are equivalent. To overcome this simplifying 250 
assumption and to get a more precise calculation tool, a new expression has been derived in this work (Eq. 251 
3, Appendix A). It also assumes the protein as the only fluorophore agent in the biological system but it 252 
embodies the free drug concentration. Experimental data for interactions of warfarin with both albumins, 253 
HSA and BSA, were fitted to Eq. 3 and the results are shown in Table 2. 254 
Literature binding parameters for warfarin-HSA interaction were measured in PBS buffer at various ionic 255 
strength levels. Kb values derived from solutions with high NaCl contents are about 3x105 and reported 256 
stoichiometry ranges between 0.5 and 1.4, see Table 1. It should be noticed the decrease in Kb and n values 257 
with the increase of the NaCl content, as stated in the systematic Bolel’s study [20]. This behavior can be 258 
explained since chloride anions present in the solution compete with warfarin resulting in a decrease in 259 
estimated warfarin-albumin binding constant [21,22]. Despite NaCl addition to buffer solutions is not 260 
mentioned in a couple of literature reports [10,23], the buffer preparation itself requires non-negligible HCl 261 
amount if the very common Na2HPO4 is the main chemical used. Unfortunately, detailed buffer preparation 262 
is not described in the original manuscripts. Results from this work (HEPES buffer 50 mM and chloride about 263 
30 mM) show a stoichiometry close to the unity but a binding constant which is almost one order of 264 
magnitude lower than most values previously published. This result could be attributed to the used fitting 265 
model (Eq. 3) since slightly higher binding quantities were obtained when the same experimental data pool 266 
was fitted to the common Eq. 2 (n=1.0; Kb=8.2x104). The recalculated Kb remains, however, somewhat lower 267 
than most values displayed in Table 1 showing that used background solutions must be considered in 268 
comparative studies. To verify again the working solution effect, Table 2 also includes the in-house results 269 
obtained in PBS, which agree with those previously published and shown in Table 1. In any case, final results 270 
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achieved in this work show an equimolar drug-protein interaction and a binding constant strongly consistent 271 
with the value attained by ITC in identical working conditions. 272 
Literature data for warfarin-BSA interaction show a similar behavior. Thus Kb value evaluated from FS 273 
measurements in buffered solutions with a high content of NaCl is lower than the one obtained in plain 274 
buffer, see Table 1. Our own measurements lead to a binding constant value consistent with that reported 275 
by Poor [2] and, such as in warfarin-HSA instance, when Eq. 2 was used slightly higher binding parameters 276 
were obtained (n=1.1; Kb=3.0x105). To evaluate again the combined effect of buffer and chloride ions, new 277 
measurements in PBS buffer were performed. As expected calculated binding constant is about five times 278 
the one obtained in HEPES buffer, revealing again the significant role of the working solution composition, 279 
see Table 2. 280 
Finally, the fit of Kb values at various temperatures to the Vant’Hoff equation (Eq. 4) (slope = 2819, intercept 281 
= 1.22, n = 3 and R2 = 0.966 for HSA; and slope = 1621, intercept = 5.92 , n = 4 and R2 = 0.982 for BSA) allows 282 
the estimation of the molar enthalpy variation involved in each interaction. Results are gathered in Table 2, 283 
showing the consistency achieved from both ITC and FS approaches.  284 
 285 
3.1.3  FA/CE measurements 286 
Table 1 shows two distinct binding steps for warfarin-albumin interaction when measured by any separation 287 
technique. Working temperature was 25 or 37 ºC but no significant differences in final results were reported.  288 
Warfarin-HSA interaction plot measured in HEPES buffer is shown in Figure 2A. It suggests two successive 289 
steps that were verified by means of the Scatchard and Klotz linear approaches. Experimental data were 290 
adjusted to Eq. 5 and derived parameters indicate very similar binding constants for both binding episodes, 291 
see Table 2. The high stoichiometry value for the first one and the similarity between both binding constants 292 
suggest some overlap between both steps in working conditions. Thus, results show the lower differentiating 293 
ability of HEPES irrespective PBS buffer (see Table 1) pointing out, however, the presence of higher order 294 
binding events, which are common when a charged species tents to interact with a poly-charged protein [12]. 295 
Figure 2B depicted the binding curve for warfarin-BSA. Data were treated in the same way explained for HSA 296 
and binding parameters of successive episodes were calculated and included in Table 2. Values related to the 297 
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first binding step are consistent with literature whereas Kb for the second one is somewhat higher than those 298 
previously published, see Tables 1 and 2.  299 
 300 
3.2 Some remarks about the binding results 301 
Despite the diversity among the evaluated quantities by the used analytical tools (ITC, FS and FA/CE), binding 302 
constant values determined in HEPES buffer for warfarin-albumin first interaction event is strongly consistent 303 
for both tested albumins, HSA or BSA. Nevertheless, the drug/protein ratio is the unity when measured by FS 304 
whereas results from ITC lead to a binding stoichiometry slightly higher than the unity for HSA and twice than 305 
expected for BSA. These last values can be attributed to some contribution of high order interactions clearly 306 
shown by FA/CE, the only approach able to detect two distinct binding episodes for studied systems. The 307 
same reason could explain the stoichiometry higher than the unity for the first binding events measured by 308 
FA/CE. To evaluate properly these results, it should be taken into account that binding affinity values 309 
obtained by FS just took in consideration the location of fluorophores since such technique simply measures 310 
the local changes around them whereas the calorimetric approach considers the overall global changes [22]. 311 
CE/FA also measures the global interaction because the mobility of the entire species is involved in 312 
calculations. Nevertheless, Kb values evaluated by the three selected approaches are consistent (Table 2) and 313 
all tested techniques should be considered suitable tools to solve the problem in hand. 314 
In summary, at least two distinct binding events are involved in studied interactions. First episode binding 315 
constants are robust being the value for warfarin-HSA about one half order of magnitude lower than that of 316 
warfarin-BSA (Table 2). Higher order binding events involve similar energy in both instances.  317 
Since this work is performed in HEPES buffer and most literature binding values have been derived from PBS 318 
buffered solutions, a comment about the buffer effect on binding parameter values seems to be appropriate. 319 
Then, regarding warfarin-HSA first interaction, ITC results obtained from both buffered solutions agree, 320 
whereas binding values from PBS solutions are about one order of magnitude higher than those obtained 321 
from HEPES buffer when FS or FA/CE were used. By contrast, values obtained for warfarin-BSA interaction in 322 
both buffered solutions are consistent. For both albumins, PBS buffer allows better resolution between 323 
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successive binding events than HEPES buffer. Thus, background solution significantly affects the binding 324 
parameters and should be considered in further biological studies. 325 
 326 
4. Conclusions 327 
Thermodynamics of warfarin-albumin interactions in strictly controlled conditions (HEPES buffer, pH 7.4 and 328 
ionic strength 50 mM) can be successfully evaluated by means of several analytical techniques (ITC, FS or 329 
FA/CE). Experimental conditions such as pH, buffering agent and contents of chloride ions in working 330 
solutions should be fixed to get reliable binding values. HEPES buffer is considered free of common side 331 
reactions often present in biochemical systems and lead to reliable binding parameters. Thus, first interaction 332 
step binding values obtained by means of the selected techniques are strongly consistent and, in case of HSA, 333 
somewhat lower than those derived from PBS buffer. Warfarin-BSA system shows similar binding parameters 334 
when measured from both buffers, HEPES and PBS. 335 
Regarding to studied systems, FS can be strongly recommended when only first binding event should be 336 
considered, whereas ITC or FA/CE should be selected for consideration of global binding process. ITC allows, 337 
in addition, an accurate evaluation of thermodynamic binding parameters.  338 
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 354 
Figure captions 355 
Figure 1: ITC titration curves of serum albumin (A: HSA; B: BSA) with warfarin 356 
 357 
Figure 2 : FA/CE binding curves for warfarin-albumin system (A: HSA; B: BSA) 358 
Table 1. Literature data for interactions between warfarin and human (HSA) or bovine (BSA) serum albumin 359 
n1 Kb1 (M) ΔH1(Kcal/mol) n2 Kb2 (M) pH T (˚C) Buffer (concentration or ionic strength, I) Experimental  technique* Reference 
          
HSA          
          
0.97 1.63x105 -3.06 - - 7.13 25 Tris (I=100 mM) ITC [16] 
0.85 4.9x104 -4.83 - - 7.13 25 MOPS (I=100 mM) ITC [16] 
0.98 6.6x104 -6.24 - - 7.13 25 Phosphate (I=100 mM) ITC [16] 
1 1.4x106 - - - 7.3 25 Phosphate (5 mM) FS [20] 
0.7 8.6x105 - - - 7.3 25 Phosphate (5 mM)+ NaCl (50 mM) FS [20] 
0.5 4.5x105 - - - 7.3 25 Phosphate (5 mM)+ NaCl (200 mM) FS [20] 
0.88 3.59x105 -1.2 - - - 27 Phosphate (10 mM) +NaCl (0.9%) FS [24] 
- 2.4x105 -- - - 7.4 25 Phosphate (9.5 mM) + NaCl (137 mM) FS [2,25] 
- 2.3x103 - - - - 25 Phosphate (50 mM) + NaCl (100 mM) FS [26] 
- 2.8x105 - - 1.4x104 7.4 25 Phosphate (67 mM) FS [10] 
1.38 3.30x105 - - - 7.4 25 Phosphate (67 mM) FS [23] 
1.5 1.1x105 - 2.9 7.7x103 7.4 37 Phosphate (67 mM) CE/FA [27] 
1.4 1.2x105 - 2.8 1.2x104 7.4 37 Phosphate (67 mM) CE/FA [28] 
1.0 3x105 - 2.8 7.4x103 7.4 27 Phosphate (67 mM) CE/FA [29] 
2.3 4.0x104 - 2.8 3.5x102 7.4 - Phosphate (66.7 mM) CE/FA*** [30] 
- 1.67x105 -5.3** - 4.83x104 7.4 37 Phosphate (66 mM) ED [31] 
1 3.04x105 - 2 2.92x104 7.4 25 Phosphate (67 mM) ED [3] 
- 2.14x105 - - - - - - Various [32] 
1 3.4x105 - - - 7.4 - - - [21] 
- 2.4x105 - - - - - - - [33] 
          
BSA          
2.5 4.76x104 - - - 7.4 25 Phosphate (50 mM) ITC [9] 
- 8.7x104 - - - 7.4 - Phosphate FS [2] 
- 2.9x104 - - - 7.4 25 Phosphate (50 mM)+NaCl (100 mM) FS [26] 
1.2 1.8x105 - 2.5 5.6x103 7.4 - Phosphate (67 mM) CE/FA [29] 
1.09 2.4x105 - 1.92 4.1x103 7.4 - Phosphate (67 mM) CE/FA [11] 
1 2.65x105 - 2 2.02x104 7.4 25 Phosphate (67 mM) ED [3] 
 360 
*Acronyms. ED: Equilibrium Dialysis; FS: Fluorescence Spectroscopy; ITC: Isothermal Titration Calorimetry; CE/FA: Capillary Electrophoresis Frontal Analysis; 361 
** Value associated to the global interaction (two steps); *** Coated capillary with polyelectrolyte multilayers 362 
  363 
 Table 2.  Binding parameters for warfarin and human (HSA) or bovine (BSA) serum albumin interactions obtained in this work. Experimental conditions: Buffer, 364 
HEPES or PBS (phosphate), pH 7.4; Temperature, 25 ºC. 365 
 366 
Buffer n1 Kb1 (M) 
ΔH1 
(Kcal/mol) n2 Kb2 (M) 
Experimental technique 
(working molar ratio range) 
       
HSA       
HEPES 50 mM 
I=50mM 1.21±0.18 (7.08±2.00)x10
4 -5.4±2.1 - - ITC      (0.1-3.5 ) 
HEPES 50 mM 
I=50mM 0.92±0.01 (4.21±0.51)x10
4 -5.6±1.0 - - FS        (0.1-5.0) 
HEPES 50 mM 
I=50mM 1.95±0.10 (3.7±0.4)x10
4 - 3.6±0.2 (1.03±0.09)x104 FA/CE (Step 1:  0.3-4.5;   Step 2:  5.0- 13.2) 
PBS 10 mM 
I=150mM 1.12±0.02 (3.18±1.5)x10
5 -4.0±0.6 - - FS        (0.3-14) 
       
BSA       
HEPES 50 mM 
I=50mM 2.20±0.13 (1.2±0.8)x10
5 -4.3±0.9 - - ITC        (0.1-4.5) 
HEPES 50 mM 
I=50mM 0.96±0.01 (0.8±0.1)x10
5 -3.7±0.1 - - FS        (0.1-5.0) 
HEPES 50 mM 
I=50mM 1.62±0.08 (1.08±0.22)x10
5 - 2.25±0.06 (2.28±0.31)x104 FA/CE (Step 1:  0.4-3.0;  Step 2:  3.0-8.0) 
PBS 10 mM 
I=150mM 1.14±0.01 (5.1±1.6)x10
5 -4.5±0.6 - - FS        (0.3-12.5) 
 367 
 368 
  369 
Table 3. Stern-Volmer parameters for warfarin-albumin interaction 370 
Albumin T (oC) Ksv Intercept R2 
HSA 25 (8.46 ± 0.07)×104 0.99 ± 0.01 0.9991 
 30 (8.39 ± 0.07)×104 1.00 ± 0.01 0.9989 
 37 (8.29 ± 0.10)×104 0.99 ± 0.01 0.9983 
BSA 18 (1.29 ± 0.01)×105 0.93 ± 0.01 0.9993 
 25 (1.18 ± 0.01)×105 0.94 ± 0.01 0.9992 
 30 (1.16 ± 0.01)×105 0.95 ± 0.01 0.9988 
 37 (1.08 ± 0.01)×105 0.98 ± 0.01 0.9993 
 371 
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APPENDIX A
According to the following binding process
P + nD           DnP
the association constant (binding constant) is defined by:
(Eq. A.1)   nff nass DP
PD
K 
where [DnP], [Pf] and [Df] are the concentrations of drug-protein complex, free protein and free 
drug, respectively, being n the number of binding sites.
According to the mass balances 
(Eq. A.2)]PD[]P[]P[]P[]P[ nfbfT 
(Eq. A.3)]PD[n]D[]D[]D[]D[ nfbfT 
where  is the concentration of bonded protein and  is the concentration of bonded ]P[ b ]D[ b
drug, and substituting equations (A.1) and (A.2) into equation (A.3), equation (A.4) is obtained:
(Eq. A.4)
   
      fT
n
1
fass
fT
T PPnPK
PP
]D[ 


 
If protein is the only fluorescent component in the considered system, then
(Eq. A.5)
 
 T
f
o P
P
F
F 
where Fo and F are the fluorescence intensities of protein in absence and presence of 
quencher, respectively.
Substituting equation (A.5) into equation (A.4), the following equation is derived:
(Eq. A.6)  


 


 
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n
1
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o
T F
FF
Pn
FK
FF
]D[
